India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.

The Indian pharmaceutical and healthcare industry has high expectations from the upcoming Union Budget 2025, according to a ...

Mankind Pharma shed 2.76% to Rs 2,560.05 after the company's consolidated net profit declined 16.2% to Rs 380.23 crore in Q3 FY25 as against Rs 453.76 crore posted in Q3 FY24.

Former prime minister late Manmohan Singh's role in the 1991 economic reforms marked a turning point for India’s ...

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for ...

Andhra Pradesh, India - A Massive fire erupted at a private pharmaceutical company, extinguished within 20 minutes made the ...

Strides Pharma share price has fallen over 10% in one month and 16% in three months. However, Strides Pharma stock has ...

Indian pharma exudes confidence to sustain US market presence under President Trump’s regime: Nandita Vijayasimha, Bengaluru Thursday, January 23, 2025, 08:00 Hrs [IST] Indian p ...

Last year in November, Strides Pharma announced the approval from National Company Law Tribunal (NCLT) for OneSource, ...

This announcement comes after a previous decision to add six companies to the F&O segment, namely Castrol India, Gland Pharma ...

The FY26 budget must focus on increasing healthcare funding, R&D tax incentives and GST reduction to enhance accessibility ...

Seeks support of Indian ambassador in Switzerland in this regardExplains the new industrial policy recently announced by CM ...